Click Here to
Subscribe
Breaking
News, Updates,
& More
Stay Up
to Date

Genetic Counseling

The ability to analyze multiple genes at the same time has led to the estimate that 20% to 25% of women with ovarian cancer have an inherited mutation in a cancer‑predisposing gene. Although this association has been noted for a while, until recently there was not enough data available to determine the lifetime ovarian cancer risk for women with a mutation in some of these genes.

The US Food and Drug Administration (FDA) has approved Inform Dual ISH (Ventana Medical Systems), a genetic test that allows for measurement of the number of copies of the HER2 gene in tumor tissue. This method of identification of women with breast cancer who are HER2-positive pinpoints who is, and who is not, a candidate for Herceptin (trastuzumab).

 


Results 1 - 2 of 2